We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue

This study is currently recruiting participants.
Verified August 2017 by Norwegian University of Science and Technology
Sponsor:
ClinicalTrials.gov Identifier:
NCT00184210
First Posted: September 16, 2005
Last Update Posted: August 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
The Research Council of Norway
The Norwegian Women´s Public Health Association
Information provided by (Responsible Party):
Norwegian University of Science and Technology
September 12, 2005
September 16, 2005
August 22, 2017
January 2000
December 2020   (Final data collection date for primary outcome measure)
MRimage of breast cancer tissue [ Time Frame: 0 hour ]
Not Provided
Complete list of historical versions of study NCT00184210 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue
HR MAS MR Spectroscopy of Breast Cancer Tissue

Breast cancer tissue is collected from women undergoing scheduled surgery for breast cancer. The tissue specimen are analyzed by MR spectroscopy. After MR, the intact tissue specimen can be analyzed by other methods, such as histopathology.

The MR spectral profiles are compared to clinical findings such as the patients diagnosis, lymph node status and tumor size.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:
tissue
Non-Probability Sample
women in surgery for breast cancer
Breast Neoplasms
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
December 2020
December 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Palpable breast cancer lesion
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact: Beathe Sitter, PhD +47 73 55 13 53 beathesi@ntnu.no
Contact: Tone F Bathen, PhD +47 73 86 38 44 tone.bathen@ntnu.no
Norway
 
 
NCT00184210
154080/I30
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Norwegian University of Science and Technology
Norwegian University of Science and Technology
  • The Research Council of Norway
  • The Norwegian Women´s Public Health Association
Study Chair: Tone F Bathen, PhD Norwegian University of Technology and Science
Norwegian University of Science and Technology
August 2017